JP2016520583A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520583A5
JP2016520583A5 JP2016512227A JP2016512227A JP2016520583A5 JP 2016520583 A5 JP2016520583 A5 JP 2016520583A5 JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016512227 A JP2016512227 A JP 2016512227A JP 2016520583 A5 JP2016520583 A5 JP 2016520583A5
Authority
JP
Japan
Prior art keywords
polypeptide
pappalysin
stanniocalcin
agent
interacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520583A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2014/050131 external-priority patent/WO2014180485A2/en
Publication of JP2016520583A publication Critical patent/JP2016520583A/ja
Publication of JP2016520583A5 publication Critical patent/JP2016520583A5/ja
Pending legal-status Critical Current

Links

JP2016512227A 2013-05-10 2014-05-12 パッパリシンレギュレーター Pending JP2016520583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370259 2013-05-10
DKPA201370259 2013-05-10
PCT/DK2014/050131 WO2014180485A2 (en) 2013-05-10 2014-05-12 Pappalysin regulator

Publications (2)

Publication Number Publication Date
JP2016520583A JP2016520583A (ja) 2016-07-14
JP2016520583A5 true JP2016520583A5 (enExample) 2017-06-15

Family

ID=50943008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512227A Pending JP2016520583A (ja) 2013-05-10 2014-05-12 パッパリシンレギュレーター

Country Status (9)

Country Link
US (2) US20160151405A1 (enExample)
EP (1) EP2994158A2 (enExample)
JP (1) JP2016520583A (enExample)
CN (1) CN105263510A (enExample)
CA (1) CA2911933A1 (enExample)
EA (1) EA201591894A1 (enExample)
HK (1) HK1215929A1 (enExample)
MX (1) MX2015015519A (enExample)
WO (1) WO2014180485A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115835879A (zh) * 2020-06-30 2023-03-21 国立大学法人东北大学 Stat3磷酸化抑制剂、自身免疫性疾病和冠状病毒传染病的预防或治疗剂
TW202235618A (zh) * 2021-01-05 2022-09-16 美國馬友醫藥教育研究基金會 治療眼內壓相關疾患
US20240301503A1 (en) * 2021-06-22 2024-09-12 Dong-A University Research Foundation For Industry-Academy Cooperation Novel biomarker for diagnosing and predicting metastasis or prognosis of various cancers, and use
WO2024042220A1 (en) * 2022-08-25 2024-02-29 Aarhus Universitet Modulators of papp-a activity
JP2025539937A (ja) 2022-11-15 2025-12-10 カリコ ライフ サイエンシーズ エルエルシー 抗ｐａｐｐ－ａ抗体及びその使用方法
WO2026008015A1 (en) * 2024-07-05 2026-01-08 The University Of Hong Kong Stanniocalcin 2 (stc2) and derivatives as anti-diabetic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994103A (en) * 1995-06-02 1999-11-30 Human Genome Science, Inc. Human stanniocalcin-alpha
CA2387685A1 (en) * 1999-10-27 2001-05-03 Human Genome Sciences, Inc. Stanniocalcin proteins and nucleic acids and methods based thereon
CA2389751A1 (en) 1999-11-01 2001-05-10 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
US20050009136A1 (en) 2003-02-19 2005-01-13 Dyax Corporation PAPP-A ligands
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
WO2009015050A2 (en) 2007-07-20 2009-01-29 The Gov. Of The U.S.A. As Represented By The Secretary Of The Department Of Health & Human Services Gene expression profile for predicting ovarian cancer patient survival
MX2010008083A (es) 2008-01-25 2010-12-20 Univ Aarhus Inhibicion de exositios selectivos de actividad papp-a contra igfbp-4.
WO2010020004A1 (en) * 2008-08-22 2010-02-25 Children's Medical Research Institute Compositions and methods for inhibition of adipogenesis and the treatment of obesity

Similar Documents

Publication Publication Date Title
Fossmark et al. Adverse effects of proton pump inhibitors—evidence and plausibility
Uchiyama et al. Proton pump inhibitors and oncologic treatment efficacy: a practical review of the literature for oncologists
Rajabi et al. The role of angiogenesis in cancer treatment
Mercer et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
JP2012019790A5 (enExample)
JP2015508063A5 (enExample)
UA113712C2 (xx) Антитіло до fap і способи його застосування
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
PH12016502345B1 (en) Anti-gitr antibodies and methods of use thereof
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
JP2018501197A5 (enExample)
FI3218406T4 (fi) Cd73:lle spesifisiä sitojamolekyylejä ja niiden käyttöjä
JP2016537383A5 (enExample)
JP2017508475A5 (enExample)
JP2018052979A5 (enExample)
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
JP2016169229A5 (enExample)
JP2017113019A5 (enExample)
JP2016512214A5 (enExample)
WO2017062496A3 (en) Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
BR112018011390A2 (pt) compostos de quinolina, método de preparação dos mesmos, e uso dos mesmos como fármaco inibidor de transportador de urato
JP2017530372A5 (enExample)
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их